EN DE
Watch Edgewise Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Edgewise Therapeutics Inc (EWTX) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Edgewise Therapeutics Inc stock $28.42, price $43.68, that is 34.9% below the price, quality 32 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US28036F1057

ET Edgewise Therapeutics Inc logo Thin data Nov 16, 2026

Edgewise Therapeutics Inc

EWTX · US

Expensive (fair value 35% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Recent news mostly positive 
Costs just 5.2 times its yearly profit. 
Insiders sold $10.0M (6M) 
Fair value $28.42 · Overvalued 
Quality 32/100 
Negative free cash flow 
Trails peers (1/7) 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch Edgewise Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$48.74 $5.51 Fair Value $28.42 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range $5.51 – $48.74 · fair‑value band $21.32 – $35.53 · the $43.68 price screens above the $28.42 fair value. As of Nov 16, 2026.

Follow Edgewise Therapeutics in your weekly email

Every Wednesday you see whether Edgewise Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.

Show moreShow less

Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.

The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction.

In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Stock analysis

Edgewise Therapeutics Inc (EWTX) currently trades at $43.68, while our estimate is $28.42, 35% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $21.32 (bear) to $35.53 (bull), the price of $43.68 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Edgewise Therapeutics Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$168M in FY2025.

Key figures

Market cap $4.7B Mid · P/E ratio 5.2 · EPS (TTM) $8.38 · Return on equity −38.0% · Return on assets (EBIT) −24.4% (5-year average) · Free cash flow −$144M · Net cash $57.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

Analysts expect earnings well below the last reported figure (earnings in transition, for example expiring patents or contracts); a fair value that looks fair on trailing earnings may then be too optimistic.

The share trades about 10% below its 52-week high and 109% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −35%, EWTX screens richer than that median.

Fair Value

Bear $21.32 Fair Value $28.42 Bull $35.53
Price $43.68 · Downside -34.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 36
Are margins and returns getting better?
Cashflow 24
Do the profits arrive as real cash?
Financial strength 84
Debt, balance sheet and risk of trouble
Investment 27
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 78
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 91
Distance to the 52-week high, does not count
New shares 17
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 6 officers or directors sold shares worth $10.0M and none bought.

  • SaleMichael NofiChief Financial Officer4,442 shares at $45.43$201,787Nov 10, 2026
  • SaleJoanne M. DonovanCMO5× since Mar 27, 2026: 131,029 shares, avg. $35.28$4.6MAug 13, 202610b5-1 plan
  • SaleKevin KochPresident and CEO, Director17,971 shares at $43.68$785,050Aug 12, 2026
  • SaleJohn R MooreGeneral Counsel5,016 shares at $43.83$219,830Aug 12, 2026
  • SaleBehrad DerakhshanChief Business Officer5,100 shares at $43.81$223,420Aug 12, 2026
  • SaleAlan J RussellChief Scientific Officer, Director2× since Jul 1, 2026: 205,901 shares, avg. $39.53$8.1MAug 12, 2026
  • SaleBadreddin EdrisDirector115,471 shares at $29.44$3.4MJan 21, 202610b5-1 plan

Plus 9 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

EWTX screens overvalued: fair value 35% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Recent news

News mood ⓘNews mood, the average tone of recent news (85 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.
Note from the team Nov 14, 2026
AI conclusion: The business shows a narrow moat with extended cash runway from the program sale as main strength, yet its weak point remains total dependence on a single Phase 3 cardiovascular candidate.
Main risk: Failure of EDG-7500 to succeed in its Phase 3 hypertrophic cardiomyopathy trial would remove the company's only remaining asset and halt all development progress.
Edgewise shifted to a pure cardiovascular focus after selling its muscular dystrophy program mid-year. The resulting cash supports operations deep into the next decade, yet success now hinges entirely on EDG-7500 clearing a sizable Phase 3 in hypertrophic cardiomyopathy. Does the narrower pipeline speed up execution or heighten the risk of any one delay?
Join the discussion →

Compare Edgewise Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Below median
Fair Value upside −34.9% · Below median
Profitability
Return on assets −30.4% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 5.2× · Cheapest 25%
P/B 9.01× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs EWTX
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs EWTX
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs EWTX
argenx SE ARGX $950.95 $908.40 −4% vs EWTX
CSL Limited CSL A$199.55 A$186.49 −7% vs EWTX
Moderna, Inc MRNA $215.27 $135.64 −37% vs EWTX
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs EWTX
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs EWTX
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs EWTX
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs EWTX

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Edgewise Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Edgewise Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/EWTX

Frequently asked questions

Is Edgewise Therapeutics Inc (EWTX) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is $28.42 versus a price of $43.68, about 35% lower (overvalued).
What is the fair value of EWTX?
Our estimate for Edgewise Therapeutics Inc is $28.42 (as of Nov 16, 2026), built from audited fundamentals. The current price: $43.68.
What is the quality score of EWTX?
Edgewise Therapeutics Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Edgewise Therapeutics Inc (EWTX)?
Our calculated price target is the estimate of $28.42 (as of Nov 16, 2026). Cautious scenario $21.32, optimistic scenario $35.53. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Edgewise Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at $28.42, about 35% lower versus a price of $43.68 (overvalued). Cautious scenario $21.32, optimistic scenario $35.53. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Edgewise Therapeutics Inc (EWTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Edgewise Therapeutics Inc it is $28.42 per share (as of Nov 16, 2026), against a price of $43.68.
Is Edgewise Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 16, 2026, EWTX trades above its calculated fair value: price $43.68, fair value $28.42, a gap of about −35% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EWTX?
No. The price is what the market pays today ($43.68); the fair value is what the company's own numbers justify ($28.42). For Edgewise Therapeutics Inc the two are $15.26 per share apart. That gap is exactly why we show both numbers side by side.
How much is Edgewise Therapeutics Inc worth?
The market values Edgewise Therapeutics Inc at about $4.7B (market capitalisation, as of Nov 16, 2026). Per share that is $43.68; our models calculate a fair value of $28.42 per share.
What do the bullish and bearish scenarios say about EWTX?
Our models span a range for Edgewise Therapeutics Inc: cautious scenario $21.32, base $28.42, optimistic $35.53 per share (as of Nov 16, 2026, price $43.68). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EWTX?
Edgewise Therapeutics Inc trades at a price-to-earnings ratio of 5.2 (as of Nov 16, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $28.42 is built from several models across several years. Other multiples: P/B 9.0.
How solid is the balance sheet of Edgewise Therapeutics Inc (EWTX)?
Balance-sheet figures for Edgewise Therapeutics Inc (as of Nov 16, 2026): return on equity −38.0%. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is EWTX from its 52-week high?
Edgewise Therapeutics Inc trades at $43.68, about 10% below its 52-week high of $48.74 and 109% above the low of $20.94 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $28.42 is for.
Which stocks are comparable to Edgewise Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Edgewise Therapeutics Inc stock attractive at the current price?
The data as of Nov 16, 2026: price $43.68, calculated fair value $28.42 (−35%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Edgewise Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Edgewise Therapeutics Inc (EWTX)?
The closing price on Nov 16, 2026 was $43.68. Our estimate is $28.42, about 35% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Edgewise Therapeutics Inc right now?
The price sits above even our optimistic bull case ($35.53). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Edgewise Therapeutics Inc

How large is the market capitalisation of Edgewise Therapeutics Inc (EWTX)?
The market capitalisation of Edgewise Therapeutics Inc is $4.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Edgewise Therapeutics Inc (EWTX)?
Earnings per share at Edgewise Therapeutics Inc are $8.38 (price ÷ EPS = P/E 5.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Edgewise Therapeutics Inc (EWTX)?
The return on equity (ROE) of Edgewise Therapeutics Inc is −38.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Edgewise Therapeutics Inc (EWTX)?
On an EBIT basis the return on assets of Edgewise Therapeutics Inc is −24.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Edgewise Therapeutics Inc (EWTX) generate?
The free cash flow of Edgewise Therapeutics Inc is −$144M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Edgewise Therapeutics Inc (EWTX) hold?
Edgewise Therapeutics Inc holds more cash than debt, $57.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Edgewise Therapeutics Inc in the live analysis

One click puts Edgewise Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.